Evidence map›Paper›PMID 26453222›Full record

Trial reportWorld journal of urology2016

A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms.

Ahmed R El-Nahas, Mohamed Tharwat, Mohamed Elsaadany, Ahmed Mosbah, Mohamed A Gaballah

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01880619 (A Randomized Clinical Trial Comparing Alpha Blacker), which is not on this map. Cited by 22 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 5 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01880619 phase4completednot on this map

A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms

TypeinterventionalSponsorMansoura UniversityRan2013 to 2014Enrolled131ConditionsRelieve of Ureteral Stent SymptomsArmsTamsulosin, Solifenacin, Control
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Pharmacological treatment of bladder stent symptoms.Bladder (San Francisco, Calif.) · 2024
    Review
  15. Canadian Urological Association guideline: Management of ureteral calculi - Abridged version.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
  16. Canadian Urological Association guideline: Management of ureteral calculi - Full-text.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
  17. Review
  18. Ureteral Stent Discomfort and Its Management.Current urology reports · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ahmed R El-NahasUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. ar_el_nahas@yahoo.com.
Mohamed TharwatUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mohamed ElsaadanyUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ahmed MosbahUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mohamed A GaballahUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the effectiveness of tamsulosin and solifenacin in relieving ureteral stents related symptoms. PATIENTS AND

methodsA randomized controlled trial was conducted between January 2013 and July 2014. Inclusion criteria were patients aged 20-50 years who underwent temporary unilateral ureteral stent for drainage of calcular upper tract obstruction or after ureteroscopic lithotripsy. Patients with history of lower urinary tract symptoms before stent placement, stents that were fixed after open or laparoscopic procedures, and those who developed complications related to the primary procedure were not included. Eligible patients were randomly assigned to 1 of 3 groups using computer-generated random tables. Patients in group 1 received placebo, patients in group 2 received tamsulosin 0.4 mg once daily, and those in group 3 received solifenacin 5 mg once daily. Ureteral Stent Symptom Questionnaire (USSQ) was answered by all patients 1-2 weeks after stent placement. The primary outcome was the comparison of total score of USSQ between all groups.

resultsThe study included 131 patients. All baseline characteristics (age, sex, side, indication, length, and duration of stent) were comparable for all groups. Total USSQ score was 61 in solifenacin group, 76 in tamsulosin group, and 83 in control group (P < 0.001). The total USSQ scores and all domains, except sexual index, were significantly better in solifenacin than in tamsulosin group (P < 0.05).

conclusionThe use of tamsulosin alone or solifenacin alone in patients with ureteral stents can improve the quality of life by decreasing ureteral stent-related symptoms. Solifenacin was better than tamsulosin. CLINICALTRIAL. GOV IDENTIFIER: NCT01880619.

Indexed as

Adrenergic alpha-AntagonistsAdultCholinergic AntagonistsFemaleHumansMaleMiddle AgedPostoperative ComplicationsSolifenacin SuccinateStentsSulfonamidesTamsulosinUreteral DiseasesAdrenergic alpha-AntagonistsCholinergic AntagonistsSolifenacin SuccinateSulfonamidesTamsulosinAlpha blockersAnticholinergicQuality of lifeSymptomsUreteral stent

Identifiers

PMID26453222
OpenAlexW1939567798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.